Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring the effect of oral anticoagulants during cardiac catheterisation
NL-OMON50931Phase 4Completed
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Feb 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heparin in coronary arteriosclerosis (3 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Laboratory coagulation measurements, Advanced coagulation and fibrinolysis markers and 7 more. Started Feb 2022; status: completed.
02
Drugs
heparin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON50931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50931.